EGFR and colorectal carcinoma: Small molecules that degrade both β-catenin and RAS via EGFR transcriptional repression could be a potential therapy for CRC patients with abnormally activated Wnt/β-catenin and EGFR-RAS pathways due to an increase in β-catenin, EGFR, and RAS, as well as their activation by pathologically important APC, KRAS, and EGFR mutations.